GSK announces significant survival results for Jemperli in endometrial cancer trial
In a significant development for patients with primary advanced or recurrent endometrial cancer, GSK plc (LSE/NYSE: GSK) has disclosed promising outcomes for Jemperli (dostarlimab-gxly) from ... Read More
Roche’s Tecentriq secures FDA approval for small cell lung cancer treatment
Roche’s subsidiary, Genentech, has announced a significant breakthrough with the US Food and Drug Administration (FDA) approval of Tecentriq (atezolizumab). This new approval marks a ... Read More
Clovis Oncology secures EC approval for Rubraca’s new indication in ovarian cancer treatment
In a major win for Clovis Oncology, the European Commission (EC) has granted approval for an expanded indication for its cancer drug, Rubraca (rucaparib). This ... Read More
Novartis’ Kisqali plus endocrine therapy shows significant PFS benefits in advanced breast cancer trials
Swiss pharmaceutical giant Novartis has announced that its breast cancer drug, Kisqali (ribociclib), when used in combination with endocrine therapy, has demonstrated substantial efficacy in ... Read More